BF-B Stock Analysis: Brown-Forman | NYSE
Beverages - Wineries & Distilleries | NYSE, USA | Market Cap: 12.623m USD | 12M Return: -1.9% | US1156372096 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 53.0M
EPS Trend: -61.3%
Qual. Beats: 0
Rev. Trend: -94.7%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Brown-Forman Corporation is a U.S.-based alcoholic beverage producer that manufactures, distills, bottles, and markets a broad portfolio of spirits, wines, ready-to-drink cocktails, and related products. Its brand lineup spans well-known labels such as Jack Daniels, Woodford Reserve, Old Forester, Gentleman Jack, Herradura, el Jimador, Fords Gin, Chambord, Diplomático, and several Scotch whisky brands including The Glendronach, Benriach, and Glenglassaugh. Beyond branded sales, the company also sells used barrels, bulk whiskey and wine, and provides contract bottling services.
The company distributes primarily through wholesalers, state and provincial governments, and retailers across the United States and more than a dozen international markets, including Germany, Australia, the United Kingdom, Canada, Spain, France, Mexico, Poland, Brazil, and Türkiye. As a member of the Distillers & Vintners sub-industry within Consumer Staples, Brown-Forman operates a brand-led, asset-light distribution model that relies on third-party distributors for most off-premise and on-premise reach. Founded in 1870 and headquartered in Louisville, Kentucky, the firm has been publicly traded since 1984.
- EU tariffs pressure American whiskey export revenue
- Jack Daniels volume softness pressures core shipment growth
- Premium tequila and whiskey portfolio drives margin expansion
| Net Income: 721.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 4.67 > 1.0 |
| NWC/Revenue: 70.11% < 20% (prev 67.91%; Δ 2.21% < -1%) |
| CFO/TA 0.13 > 3% & CFO 1.01b > Net Income 721.0m |
| Net Debt (2.14b) to EBITDA (1.21b): 1.77 < 3 |
| Current Ratio: 3.26 > 1.5 & < 3 |
| Outstanding Shares: last fiscal year (466.7m) vs prev -1.31% < -2% |
| Gross Margin: 60.66% > 18% (prev 59.02%; Δ 1.65% > 0.5%) |
| Asset Turnover: 48.95% > 50% (prev 48.32%; Δ 0.63% > 0%) |
| Interest Coverage Ratio: 11.20 > 6 (EBIT TTM 1.12b / Interest Expense TTM 100.0m) |
| A: 0.35 (Total Current Assets 3.96b - Total Current Liabilities 1.21b) / Total Assets 7.83b |
| B: 0.63 (Retained Earnings 4.96b / Total Assets 7.83b) |
| C: 0.14 (EBIT TTM 1.12b / Avg Total Assets 8.00b) |
| D: 1.03 (Book Value of Equity 3.97b / Total Liabilities 3.86b) |
| Altman-Z'' = 6.39 = AAA |
| DSRI: 0.98 (Receivables 822.0m/847.0m, Revenue 3.92b/3.95b) |
| GMI: 0.97 (GM 59.02% / 60.66%) |
| AQI: 1.00 (AQ_t 0.35 / AQ_t-1 0.35) |
| SGI: 0.99 (Revenue 3.92b / 3.95b) |
| TATA: -0.04 (NI 721.0m - CFO 1.01b) / TA 7.83b) |
| Beneish M = -3.08 (Cap -4..+1) = AA |
As of September 05, 2026, the stock is trading at USD 26.73 with a total of 1,991,297 shares traded. Over the past week, the price has changed by -0.96%, over one month by -5.31%, over three months by +6.80% and over the past year by -1.92%.
Current recommended Stop Loss: 24.40 (which is 8.7% or 2.8 ATR below the current price).
Brown-Forman has received a consensus analysts rating of 3.00. Therefore, it is recommended to hold BF-B.
- StrongBuy: 2
- Buy: 3
- Hold: 10
- Sell: 3
- StrongSell: 2
| Analysts Target Price | 28.1 | 5.1% |
P/E Trailing = 17.6346
P/E Forward = 15.4083
P/S = 3.2244
P/B = 3.0089
P/EG = 1.9865
Revenue TTM = 3.92b USD
EBIT TTM = 1.12b USD
EBITDA TTM = 1.21b USD
Long Term Debt = 2.08b USD (from longTermDebt, last fiscal year)
Short Term Debt = 358.0m USD (from shortTermDebt, last quarter)
Debt = 2.44b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.14b USD (calculated: Debt 2.44b - CCE 301.0m)
Enterprise Value = 14.8b USD (12.6b + Debt 2.44b - CCE 301.0m)
Interest Coverage Ratio = 11.20 (Ebit TTM 1.12b / Interest Expense TTM 100.0m)
EV/FCF = 15.96x (Enterprise Value 14.8b / FCF TTM 925.0m)
FCF Yield = 6.27% (FCF TTM 925.0m / Enterprise Value 14.8b)
FCF Margin = 23.63% (FCF TTM 925.0m / Revenue TTM 3.92b)
Net Margin = 18.42% (Net Income TTM 721.0m / Revenue TTM 3.92b)
Gross Margin = 60.66% ((Revenue TTM 3.92b - Cost of Revenue TTM 1.54b) / Revenue TTM)
Gross Margin QoQ = 60.26% (prev 62.61%)
Tobins Q-Ratio = 1.89 (Enterprise Value 14.8b / Total Assets 7.83b)
Interest Expense / Debt = 4.10% (Interest Expense 100.0m / Debt 2.44b)
Taxrate = 19.35% (173.0m / 894.0m)
NOPAT = 903.3m (EBIT 1.12b * (1 - 19.35%))
Current Ratio = 3.26 (Total Current Assets 3.96b / Total Current Liabilities 1.21b)
Debt / Equity = 0.62 (Debt 2.44b / totalStockholderEquity, last quarter 3.97b)
Debt / EBITDA = 1.77 (Net Debt 2.14b / EBITDA 1.21b)
Debt / FCF = 2.31 (Net Debt 2.14b / FCF TTM 925.0m)
Total Stockholder Equity = 4.05b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.01% (Net Income 721.0m / Total Assets 7.83b)
RoE = 17.80% (Net Income TTM 721.0m / Total Stockholder Equity 4.05b)
RoCE = 18.26% (EBIT 1.12b / Capital Employed (Equity 4.05b + L.T.Debt 2.08b))
RoIC = 13.33% (NOPAT 903.3m / Invested Capital 6.77b)
WACC = 5.50% (E(12.6b)/V(15.1b) * Re(5.93%) + D(2.44b)/V(15.1b) * Rd(4.10%) * (1-Tc(0.19)))
Discount Rate = 5.93% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -68.34 | Cagr: -1.53%
[DCF] Terminal Value 77.97% ; FCFF base≈788.6m ; Y1≈904.0m ; Y5≈1.33b
[DCF] Fair Price = 61.58 (EV 20.0b - Net Debt 2.14b = Equity 17.9b / Shares 290.4m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -61.27 | EPS CAGR: -8.13% | SUE: 0.10 | # QB: 0
Revenue Correlation: -94.73 | Revenue CAGR: -3.47% | SUE: -0.09 | # QB: 0
EPS current Quarter (2026-10-31): EPS=0.46 | Chg30d=-0.28% | Revisions=+25% | Analysts=12
EPS next Quarter (2027-01-31): EPS=0.52 | Chg30d=-0.35% | Revisions=-25% | Analysts=12
EPS current Year (2027-04-30): EPS=1.73 | Chg30d=+2.87% | Revisions=-50% | GrowthEPS=+13.1% | GrowthRev=+0.6%
EPS next Year (2028-04-30): EPS=1.70 | Chg30d=-0.16% | Revisions=-40% | GrowthEPS=-1.8% | GrowthRev=+1.5%
[Analyst] Revisions Ratio: -50% (up=1, down=6)